Orthofix International N.V. (OFIX) Set to Announce Quarterly Earnings on Monday
Orthofix International N.V. (NASDAQ:OFIX) will issue its quarterly earnings data after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Orthofix International N.V. has set its FY17 guidance at $1.54-1.60 EPS.
Orthofix International N.V. (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The business had revenue of $108.90 million during the quarter, compared to the consensus estimate of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.41 earnings per share. On average, analysts expect Orthofix International N.V. to post $1.56 EPS for the current fiscal year and $1.83 EPS for the next fiscal year.
Shares of Orthofix International N.V. (NASDAQ:OFIX) traded up 0.69% on Monday, hitting $49.84. 8,242 shares of the company’s stock were exchanged. Orthofix International N.V. has a 12-month low of $32.51 and a 12-month high of $51.09. The company’s 50-day moving average price is $48.86 and its 200 day moving average price is $44.87. The stock has a market cap of $905.59 million, a price-to-earnings ratio of 116.72 and a beta of 0.20.
In other Orthofix International N.V. news, CFO Rice Doug sold 7,353 shares of Orthofix International N.V. stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $49.46, for a total transaction of $363,679.38. Following the completion of the transaction, the chief financial officer now owns 44,743 shares in the company, valued at $2,212,988.78. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Raymond Fujikawa sold 6,364 shares of Orthofix International N.V. stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $47.06, for a total transaction of $299,489.84. Following the transaction, the insider now owns 31,084 shares of the company’s stock, valued at approximately $1,462,813.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,406 shares of company stock valued at $1,138,531. 5.60% of the stock is currently owned by company insiders.
Several analysts have recently weighed in on OFIX shares. Zacks Investment Research raised shares of Orthofix International N.V. from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. BidaskClub downgraded shares of Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. TheStreet raised shares of Orthofix International N.V. from a “c+” rating to a “b-” rating in a report on Tuesday, August 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $55.00 target price (up previously from $50.00) on shares of Orthofix International N.V. in a report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Orthofix International N.V. presently has an average rating of “Buy” and an average price target of $52.75.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.